Literature DB >> 26122628

Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI.

Mari Kärki1, Kirsti Näntö-Salonen2, Harri Niinikoski3, Laura M Tanner4.   

Abstract

OBJECTIVE: Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder affecting the transport of cationic amino acids. It has previously been shown that approximately one third of the Finnish LPI patients have impaired renal function. The aim of this study was to analyse in detail urine beta2-microglobulin values, renal dysfunction, oral L-citrulline doses and plasma citrulline concentrations in Finnish LPI patients. METHODS AND
RESULTS: Of the 41 Finnish LPI patients, 56% had proteinuria and 53% hematuria. Mean plasma creatinine concentration was elevated in 48%, serum cystatin C in 62%, and urine beta2-microglobulin in 90% of the patients. Seventeen per cent of the patients developed ESRD, and five of them received a kidney transplant. L-citrulline doses and fasting plasma citrulline concentrations were similar in adult LPI patients with decreased and normal GFR (mean ± SD 79.5 ± 29.2 vs. 82.4 ± 21.9 mg/kg/day, P = 0.619, and 80.3 ± 20.1 vs. 64.8 ± 23.0 μmol/l, P = 0.362, respectively).
CONCLUSIONS: Urine beta2-microglobulin is a sensitive early marker of renal involvement, and it should be monitored regularly in LPI patients. Weight-based oral L-citrulline doses and plasma citrulline concentrations were not associated with renal function. LPI patients with ESRD were successfully treated with dialysis and kidney transplantation.

Entities:  

Year:  2015        PMID: 26122628      PMCID: PMC5059186          DOI: 10.1007/8904_2015_465

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  31 in total

Review 1.  Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder.

Authors:  Hélène Ogier de Baulny; Manuel Schiff; Carlo Dionisi-Vici
Journal:  Mol Genet Metab       Date:  2012-02-17       Impact factor: 4.797

2.  Estimation of glomerular filtration rate by serum creatinine and serum beta 2-microglobulin.

Authors:  B Trollfors; R Norrby
Journal:  Nephron       Date:  1981       Impact factor: 2.847

3.  Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism.

Authors:  J Perheentupa; J K Visakorpi
Journal:  Lancet       Date:  1965-10-23       Impact factor: 79.321

4.  Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.

Authors:  D Torrents; J Mykkänen; M Pineda; L Feliubadaló; R Estévez; R de Cid; P Sanjurjo; A Zorzano; V Nunes; K Huoponen; A Reinikainen; O Simell; M L Savontaus; P Aula; M Palacín
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

5.  Reappraisal of serum beta2-microglobulin as marker of GFR.

Authors:  C Bianchi; C Donadio; G Tramonti; C Consani; P Lorusso; G Rossi
Journal:  Ren Fail       Date:  2001 May-Jul       Impact factor: 2.606

6.  Lysinuric protein intolerance and systemic lupus erythematosus.

Authors:  T Kamoda; Y Nagai; M Shigeta; C Kobayashi; T Sekijima; M Shibasaki; N Nakamura
Journal:  Eur J Pediatr       Date:  1998-02       Impact factor: 3.183

Review 7.  Lysinuric protein intolerance: reviewing concepts on a multisystem disease.

Authors:  Gianfranco Sebastio; Maria P Sperandeo; Generoso Andria
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-02-09       Impact factor: 3.908

Review 8.  Arginine metabolism: boundaries of our knowledge.

Authors:  Sidney M Morris
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

Review 9.  Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling.

Authors:  Masataka Mori
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

10.  Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance.

Authors:  Laura M Tanner; Kirsti Näntö-Salonen; Mohamed S Rashed; Soile Kotilainen; Maija Aalto; Jaana Venetoklis; Harri Niinikoski; Kirsi Huoponen; Olli Simell
Journal:  Metabolism       Date:  2008-04       Impact factor: 8.694

View more
  2 in total

Review 1.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

Review 2.  Amino Acid Transport Defects in Human Inherited Metabolic Disorders.

Authors:  Raquel Yahyaoui; Javier Pérez-Frías
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.